Anaconda Biomed, a medical device company, received 20 million euros in financing to promote research on the treatment of ischemic stroke

Arterial network (wechat: vcpeat) learned through foreign media information that on December 4, 2019, American medical device company anacondabimed received a new financing of 20 million euros This round of financing was led by the famous Barcelona venture capital company asabypartners, with joint investment of ysios capital, omegafunds, innogestcapital and Sabadell venture capital Anacondabimed was founded in 2015 as a Spanish medical technology company The company is committed to developing the next generation thrombectomy system for the treatment of ischemic stroke, and its flagship product is advanced thrombectomy system Anaconda's advanced thrombectomy system consists of a delivery catheter, a funnel catheter and a stent handler In the process of using the system, the catheter will automatically expand to the extent consistent with the diameter of the artery (up to 5mm), block the blood flow locally, so that the thrombus can be completely extracted without rupture in the body Developing new and more effective therapies for stroke patients is the focus of attention in the healthcare industry According to the lancet, stroke is the second most deadly disease in the world In 2016, 5.5 million people died of strokes around the world According to the 2016 global burden of disease report (GBD) in the New England Journal of medicine, the global risk of life-long stroke in people over 25 years old was 24.9% in 2016, which was higher than 22.8% in 1990 "This investment in Anaconda follows our existing investment strategy Our investment strategy focuses on breaking through the boundaries of science and technology to solve some of the most challenging medical problems," said josepll, co-founder of asabys partners "We believe Anaconda will bring the most advanced thrombectomy system to the market to effectively treat ischemic stroke," added Sylvain sachot, director of investment at asabys partners >>>>About asabyspartners, founded in 2018 and operating in 2019, is a Barcelona venture capital company The company focuses on medical technology, digital therapy and early Biopharmaceutics, supporting highly innovative and transformative technologies Since its inception, asabyspartners has invested in digital healthcare companies psious, carecare and biotechnology company onatherapeutics >>>>About omegafunds omegafunds is an investment company based on the global life science, founded in 2004, with its headquarters in Boston, Massachusetts The company funds companies that use new therapies, devices or technology platforms to address serious, unmet medical needs Since its inception, the company has raised more than $700 million.